Nephrotoxic Potential of Selective Cyclooxygenase-2 Inhibitors

Annals of Pharmacotherapy

Volumn 38, Issue 4, 2004, Pages 700-704

  Sandhu, Gurbir K ^a   Heyneman, Catherine A ^a,b  

^a IDAHO STATE UNIVERSITY   (United States)

^b Idaho Drug Information Service   (United States)

Author keywords

Celecoxib; Cyclooxygenase 2 inhibitors; Nephrotoxicity; Rofecoxib

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ABDOMINAL PAIN; COMORBIDITY; CONSTIPATION; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HUMAN; HYPERKALEMIA; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY INJURY; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; SODIUM RETENTION; URINE RETENTION;

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; KIDNEY DISEASES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES;

EID: 1542429162     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D296     Document Type: Review

References (16)

1. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999; 106(5B):13S-24S.
2. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol 1991;31:588-98.
3. Perez Gutthan S, Garcia Rodriguez LA, Raiford DS, Duque Oliart A, Ris Romeu J. Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure. Arch Intern Med 1996;156:2433-9.
4. Perazella M. COX-2 inhibitors and the kidney. Hosp Pract 2001;36:43-56.
5. Perazella MA, Eras J. Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis 2000;35:937-40.
6. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984;310:563-72.
7. Stichtenoth DO, Frolich JC. COX-2 and the kidneys. Curr Pharm Des 2000;6:1737-53.
8. Yang T, Singh I, Pham H, Sun D, Smart A, Schnermann JB, et al. Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol 1998;274(3 pt 2):F481-9.
9. Komhoff M, Grone HJ, Klein T, Seyberth HW, Nusing RM. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol 1997;272(4 pt 2):F460-8.
10. Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999;66:76-84.
11. Catella-Lawson F, McAdam B, Morrison B, Kapoor S, Kujubu D, Antes L, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999;289:735-41.
12. Whelton A, Schulman G, Wallenmark C, Drower EJ, Isakson PC, Verburg KM, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000;160:1465-70.
13. Swan S, Rudy D, Lasseter K, Ryan CF, Buechel K, Lambrecht LJ, et al. Effects of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. Ann Intern Med 2000;133:1-9.
14. Schwartz JI, Vandormael K, Malice MP, Kalyani RN, Lasseter KC, Holmes GB, et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther 2002;72:50-61.
15. Perazella MA, Tray K. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am J Med 2001;111:64-7.
16. Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, et al. Rofecoxib [Vioxx, MK-0966; 4-(4′ -Methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 1999;290:551-60.